FDG-PET/CT for diagnosis of primary ovarian cancer

BACKGROUND AND AIMTo evaluate the diagnostic value of integrated F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT) to discriminate malignant from benign ovarian tumors. METHODSOne hundred and eight women suspected of having ovarian cancer underwent preoperative FDG-PET/CT scans. FDG uptake was quantified by calculating the maximum standardized uptake value (SUVmax) of each tumor. The receiver operating characteristic curve was drawn to determine the optimal cut-off values of SUVmax that would best discriminate between benign and malignant tumors. Histopathologic results served as the reference standard. We assessed the association between SUVmax and with International Federation of Gynecology and Obsterics stage in borderline and malignant tumors, using one-factor analysis of variance and an unpaired t test with Bonferoni correction. RESULTSThe SUVmax of benign (n=26), borderline (n=12) and malignant (n=73) lesions was 2.00±1.02, 2.72±1.04, and 7.55±4.29, respectively. Although there were significant differences between benign and malignant, and borderline and malignant lesions (P